Aparna Pharmaceuticals, an Active Pharmaceutical Ingredients (APIs) and Advanced Drug Intermediate producing company announced the United States Food and Drug Administration (USFDA) clearance for its manufacturing facility, Aparna Organics, situated in Pydibhimavaram, Srikakulalam, Andhra Pradesh, India. The company in a press statement on Monday said that the USFDA conducted a thorough audit of the facility in September 2023, leading to the VAI classification.
Rakesh Reddy, the Managing Director of Aparna Pharmaceuticals, said, "This clearance is a testament to our team’s relentless pursuit of excellence. Our facility’s compliance journey has been meticulous. We are thrilled to receive the USFDA’s stamp of approval. We are excited to contribute to global healthcare by delivering high-quality pharmaceutical APIs and intermediates."
Following the successful FDA audit, Aparna Pharmaceuticals emerged as a frontrunner in the production of APIs and Advanced Drug Intermediates, gaining international recognition for delivering top-notch products manufactured under cGMP guidelines.